Introduction: Owing to their rarity, clinicopathologic variables and postoperative outcomes in patients with ampulla of Vater carcinoma (AVC) have not been fully elucidated.
Materials And Methods: A retrospective review of the clinical records of patients who underwent surgical exploration for AVC was performed using univariate and multivariate analyses.
Results: One-, three-, and five-year overall survival rates after surgery were 97.4%, 71.8%, and 63.0%, respectively. The most frequently observed sites of recurrence were lymph nodes in 11 patients (52%), followed by the liver in eight (38%), lung in six (29%), local in three (14%), and peritoneal dissemination in three (14%). On multivariate analysis, only the presence of lymph node metastasis extending to the pancreatic head region predicted inferior relapse-free survival. A significant correlation between postoperative recurrence and pathological lymph node metastasis was observed.
Conclusions: Lymph node metastasis, especially that extends to the pancreatic head region, was clearly identified as a prognostic indicator of reduced relapse-free survival in patients with AVC.
Download full-text PDF |
Source |
---|
BMC Cancer
January 2025
Department of Respiratory Medicine, First Affiliated Hospital of Huzhou University, Huzhou University, Huzhou, Zhejiang, 313000, China.
Background: LINC00312 has shown to play a suppressive role in the development and progression of non-small cell lung cancer (NSCLC). However, the expression pattern and diagnostic role of circulating LINC00312 in NSCLC remain to be confused.
Methods: A total of 319 patients diagnosed with NSCLC and 180 healthy volunteers were enrolled from the First Affiliated Hospital of Huzhou University between January, 2022 and December, 2023.
EMBO Mol Med
January 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Oncolytic viruses (OV) expressing bispecific T-cell engagers (BiTEs) are promising tools for tumor immunotherapy but the range of target tumors is limited. To facilitate effective T-cell stimulation with broad-range applicability, we established membrane-associated T-cell engagers (MATEs) harboring the protein transduction domain of the HIV-Tat protein to achieve non-selective binding to target cells. In vitro, MATEs effectively activated murine T cells and improved killing of MC38 colon carcinoma cells.
View Article and Find Full Text PDFSupport Care Cancer
January 2025
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey.
Purpose: To determine whether body awareness and upper extremity functionality are affected in patients with or without lymphedema development after breast cancer surgery (BCS) in comparison with individuals without a history of cancer.
Methods: The study included a total of 102 individuals, including 34 who developed lymphedema after BCS (mean age: 43.88 ± 12.
Ann Surg Oncol
January 2025
Division of Colorectal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, China.
Background: Local relapse has not been eradicated even in the era of total mesorectum excision. Although various approaches have been attempted, R0 resection remains the only potentially curative treatment. PATIENT AND METHODS: A 45-year-old woman with a history of laparoscopic abdominoperineal resection was diagnosed with pelvic recurrence 7 months ago.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Thoracic Surgery, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: This study aimed to evaluate the necessity of lymph node sampling for specific non-small cell lung cancer (NSCLC).
Methods: Patients with small-size (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened. The characteristics of patients with nodal metastasis were demonstrated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!